Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Hematopoietic Cell Transplantation, Version 3.2025

Hematopoietic Cell Transplantation, Version 3.2025 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Loren, A. W., Mielcarek, M., Bolanos-Meade, J., Brammer, J., Cowden, M., Di Stasi, A., El-Jawahri, A., Elmariah, H., Gundabolu, K., Gutman, J., Ho, V., Hoeg, R. T., Horwitz, M., Jamy, O., Kassim, A., Kharfan-Dabaja, M., Lee, L., Logan, A., Luszcak, C., Magenau, J. M., Martin, T. G., Mittal, V., Moreira, J., Muffly, L., Nakamura, R., Nawas, M., Nieto, Y., Ninos, C., Oliai, C., Papanicolaou, G., Pidala, J., Randolph, B., Schroeder, M. A., Tessier, J., Topal, J., Tzachanis, D., Varshavsky-Yanovsky, A., Jones, F., Stehman, K. 2025; 23 (10)

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation (HCT) provide expert, multidisciplinary recommendations for autologous and allogeneic HCT based on current evidence. The NCCN Guidelines focus on pretransplant recipient evaluation, hematopoietic cell mobilization, conditioning, and the diagnosis and management of graft-versus-host disease (GVHD), a common complication of allogeneic HCT that is associated with significant morbidity. This selection from the NCCN Guidelines for HCT focuses on the diagnosis, workup, and management of acute and chronic GVHD, as well as important supportive care considerations.

View details for DOI 10.6004/jnccn.2025.0047

View details for Web of Science ID 001605509500007

View details for PubMedID 41067275